Researchers synthesized CBD-like molecules from carvone (a spearmint compound) that showed stronger anti-seizure effects than natural CBD in mouse models of developmental epilepsy.
Epilepsy researchers, parents of children with treatment-resistant seizures, and anyone following CBD pharmacology beyond the cannabis plant.
What the researchers found
Natural CBD (marketed as Epidiolex) works for certain severe childhood epilepsy syndromes, but its effectiveness is limited and it carries regulatory complexity as a cannabis-derived product. This study took a different approach: synthesizing CBD enantiomers (mirror-image molecules) from carvone, a compound found in spearmint and caraway.
The researchers built a small library of these carvone-derived CBD variants and tested them systematically. They found that lengthening the alkyl chain (a molecular tail) increased potency, with one variant called (+)-CBD-oct showing particularly strong effects on brain wave patterns associated with seizure activity.
In mouse models, pre-treatment with (+)-CBD-oct promoted seizure resilience in both normal mice and in a genetic model of developmental epilepsy (Gabra2-1 mice, which have dysfunctional GABA receptors). The compound influenced seizure characteristics and reduced mortality. Five days of oral treatment during a critical developmental window also showed effects.
Notably, these synthetic variants affected different brain wave frequency bands (delta and theta) than natural CBD, suggesting they may work through partially different mechanisms—potentially opening the door to combination therapies.
Why it matters
Current anti-seizure medications for developmental epilepsy have significant limitations: many patients are treatment-resistant, and standard drugs that target GABA signaling can harm the developing brain. Natural CBD helps some patients but not all. These synthetic CBD analogues could expand the toolkit—and because they're derived from spearmint rather than cannabis, they sidestep some of the regulatory and supply chain issues that complicate cannabis-derived medicines.
The numbers in context
(+)-CBD-oct showed effects on both delta and theta frequency bands. Reduced seizure mortality in the Gabra2-1 epilepsy model. Longer alkyl chains correlated with greater potency across the compound library.
How the study worked
Structure-activity relationship study using EEG-based assessment in mice. Tested a library of carvone-derived CBD (+) enantiomers with varying alkyl chain lengths. Seizure resilience tested in both wildtype mice and the Gabra2-1 developmental epilepsy model. Administration routes included pre-treatment and 5-day oral gavage during postnatal development.
Who was studied
Male and female C57BL/6 mice, specific strain not detailed.
What this study cannot tell us
All data from mouse models—no human testing yet. The Gabra2-1 model represents one specific type of developmental epilepsy; results may not generalize to other epilepsy syndromes. Long-term safety of these novel compounds is unknown. The gap between promising preclinical results and clinical efficacy is notoriously large in epilepsy drug development.
How to read the evidence
Preclinical animal study with systematic structure-activity testing—promising but years away from human application.
When this study was published
Published in 2025, representing cutting-edge cannabinoid pharmacology research.
The bigger picture
This represents a broader trend in cannabinoid pharmacology: moving from crude plant extracts to precision-designed molecules that target specific mechanisms. While Epidiolex (pharmaceutical CBD) was a landmark approval for Dravet and Lennox-Gastaut syndromes, these carvone-derived variants could address the many epilepsy patients for whom CBD alone isn't enough. The non-cannabis source also matters for global access, since many countries restrict cannabis-derived products regardless of their psychoactive properties.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Will (+)-CBD-oct prove safe and effective in human epilepsy patients? Could it be combined with natural CBD for enhanced effects? Does the spearmint derivation actually simplify regulatory approval, or will these compounds face similar hurdles as cannabis-derived medicines?
Read the original research
Carvone derived cannabidiol enantiomers as novel anticonvulsants.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 50(13), 1970-1981
Neuropsychopharmacology is a reputable journal focusing on the intersection of neuroscience and pharmacology.
Citation
Hines, Rochelle M; Contreras, April; Carrillo, Adriana; Paton, Alexandra; Tenorio, Antonio J; Maio, William A; Hines, Dustin J. (2025). Carvone derived cannabidiol enantiomers as novel anticonvulsants.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 50(13), 1970-1981. https://doi.org/10.1038/s41386-025-02220-1
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk